Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
Public ClinicalTrials.gov record NCT00082121. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.
Study identification
- NCT ID
- NCT00082121
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2004 (Type not available)
- Primary completion
- Not listed
- Completion
- Dec 2005 (Type not available)
- Last update posted
- Jul 20, 2007
2004 – 2005
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | Sarasota | Florida | 34239 | — |
| Not listed | Atlanta | Georgia | 30342 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Towson | Maryland | 21204 | — |
| Not listed | Boston | Massachusetts | 02118 | — |
| Not listed | Springfield | Massachusetts | 01199 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Lansing | Michigan | 48910 | — |
| Not listed | Cincinnati | Ohio | 45219 | — |
| Not listed | Memphis | Tennessee | 38120 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Danville | Virginia | 24541 | — |
| Not listed | Madison | Wisconsin | 53792 | — |
| Not listed | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00082121, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2007 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00082121 live on ClinicalTrials.gov.